Metagenomi Inc
NASDAQ:MGX
Intrinsic Value
Metagenomi Inc is a US-based company operating in Biotechnology industry. [ Read More ]
The intrinsic value of one MGX stock under the Base Case scenario is 4.97 USD. Compared to the current market price of 7.08 USD, Metagenomi Inc is Overvalued by 30%.
Valuation Backtest
Metagenomi Inc
Run backtest to discover the historical profit from buying and selling MGX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Metagenomi Inc
Current Assets | 278.3m |
Cash & Short-Term Investments | 271.2m |
Receivables | 2.5m |
Other Current Assets | 4.6m |
Non-Current Assets | 86.6m |
Long-Term Investments | 10.7m |
PP&E | 65.2m |
Other Non-Current Assets | 10.7m |
Current Liabilities | 68.9m |
Accounts Payable | 1.8m |
Accrued Liabilities | 14.9m |
Other Current Liabilities | 52.2m |
Non-Current Liabilities | 80.8m |
Other Non-Current Liabilities | 80.8m |
Earnings Waterfall
Metagenomi Inc
Revenue
|
44.8m
USD
|
Operating Expenses
|
-123.2m
USD
|
Operating Income
|
-78.5m
USD
|
Other Expenses
|
10.2m
USD
|
Net Income
|
-68.3m
USD
|
Free Cash Flow Analysis
Metagenomi Inc
MGX Profitability Score
Profitability Due Diligence
Metagenomi Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Metagenomi Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
MGX Solvency Score
Solvency Due Diligence
Metagenomi Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Metagenomi Inc's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MGX Price Targets Summary
Metagenomi Inc
According to Wall Street analysts, the average 1-year price target for MGX is 19.58 USD with a low forecast of 10.1 USD and a high forecast of 26.25 USD.
Shareholder Return
MGX Price
Metagenomi Inc
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -59% |
Market Capitalization | 265.7m USD |
Shares Outstanding | 37 530 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Metagenomi Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Emeryville, California and currently employs 223 full-time employees. The company went IPO on 2024-02-09. Metagenomi, Inc. is a precision genetic medicine company. The firm is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). The company has also developed an expansive and modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. Its platform enables it to rapidly and effectively find, screen, and select tools with the highest targetability, specificity, and efficiency in order to develop them into genetic medicine.
Contact
IPO
Employees
Officers
The intrinsic value of one MGX stock under the Base Case scenario is 4.97 USD.
Compared to the current market price of 7.08 USD, Metagenomi Inc is Overvalued by 30%.